MedicaidReimbursementMedium impact
Adding Ocrelizumab to the Office and Outpatient Fee Schedule pdf
Connecticut Medicaid (HUSKY Health)·CT · Neurology, Rheumatology, Oncology·Reimbursement
Effective date
Mar 1, 2020
We identified it
Jun 20, 2026
Summary
Connecticut Medicaid has added HCPCS code J2350 (Ocrelizumab) to their physician office and outpatient fee schedule with a reimbursement rate of $57.42. Providers must include the 11-digit NDC number on all claims for physician-administered drugs to avoid denials.
Action Required
Effective March 1, 2020: Billing team must update fee schedules to include J2350 (Ocrelizumab) at $57.42 reimbursement rate for Connecticut Medicaid patients. Ensure all claims for physician-administered drugs include the HIPAA standard 11-digit NDC number to avoid denials or incorrect reimbursement. Reference Chapter 8 on www.ctdssmap.com for NDC formatting instructions.